Cazanat 40mg Tablet

Cazanat 40mg tablet is a prescription based medication used in the treatment of thyroid cancer. Its active ingredient is Cabozantinib that belongs to the dug class of tyrosine kinase inhibitor. The medicine works blocking the enzyme called tyrosine kinases that signal cancer cells to grow and divide. The medicine is a first line therapy as recommended by the healthcare professional. It should not be used for adults under the age of 18. Patients taking this medicine should regularly be monitored for side effects and treatment response.

Thyroid cancer

Cazanat 40mg tablet also causes many side effects like any other medication have. Patients may feel acute and severe symptoms, some may resolve on their own and some need proper medical attention. Common side effects include:
● Anemia
● Fatigue
● Nausea
● Diarrhea
● Vomiting
● High blood pressure
● Low blood platelets
● Stomatitis (Inflammation of the mouth)
● Decrease in body weight
● Increased liver enzyme
● Decreased appetite

Cazanat 40mg tablet should be taken on an empty stomach at the fixed time everyday to increase the effectiveness of the medication. The medication is taken exactly be taken as recommended by the healthcare professional to ensure safety and effectiveness of the medication. Taking it in the wrong way or taking too much can cause very serious side effects. Discuss with the doctor for proper dosage and duration of the treatment.

Thyroid cancer is caused by DNA mutation in cancer cells, leading to uncontrolled growth and tumor formation. Cazanat 40mg tablet is an anti-cancer medication, it works by blocking enzymes called tyrosine that signal cancer cells to grow and divide. It helps stop the production of cancer cells and prevents the body from multiplication of cancer cells in the body. The medicine is used as a first line therapy as it cutting off the nutrients and oxygen that a tumor needs to grow. Overall, it helps control the disease progression.

• Lacy, S. A., Miles, D. R., & Nguyen, L. T. (2017). Clinical pharmacokinetics and pharmacodynamics of cabozantinib. Clinical pharmacokinetics, 56(5), 477-491.
• Abou-Alfa, G. K., Meyer, T., Cheng, A. L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B. Y., ... & Kelley, R. K. (2018). Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. New England Journal of Medicine, 379(1), 54-63.
• El-Khoueiry, A. B., Hanna, D. L., Llovet, J., & Kelley, R. K. (2021). Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treatment Reviews, 98, 102221.
• Choueiri, T. K., Escudier, B., Powles, T., Mainwaring, P. N., Rini, B. I., Donskov, F., ... & Motzer, R. J. (2015). Cabozantinib versus everolimus in advanced renal-cell carcinoma. New England Journal of Medicine, 373(19), 1814-1823.
• Castellano, D., Apolo, A. B., Porta, C., Capdevila, J., Viteri, S., Rodriguez-Antona, C., ... & Maroto, P. (2022). Cabozantinib combination therapy for the treatment of solid tumors: a systematic review. Therapeutic advances in medical oncology, 14, 17588359221108691.